



HAL
open science

Inactivation by Hg and methylmercury of the glutamine/amino acid transporter (ASCT2) reconstituted in liposomes. Prediction of the involvement of a CXXC motif by homology modelling.

Francesca Oppedisano, Michele Galluccio, Cesare Indiveri

► To cite this version:

Francesca Oppedisano, Michele Galluccio, Cesare Indiveri. Inactivation by Hg and methylmercury of the glutamine/amino acid transporter (ASCT2) reconstituted in liposomes. Prediction of the involvement of a CXXC motif by homology modelling.. *Biochemical Pharmacology*, 2010, 80 (8), pp.1266. <10.1016/j.bcp.2010.06.032>. <hal-00618193>

HAL Id: hal-00618193

<https://hal.science/hal-00618193v1>

Submitted on 1 Sep 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Accepted Manuscript

Title: Inactivation by Hg²⁺ and methylmercury of the glutamine/amino acid transporter (ASCT2) reconstituted in liposomes. Prediction of the involvement of a CXXC motif by homology modelling.

Authors: Francesca Oppedisano, Michele Galluccio, Cesare Indiveri

PII: S0006-2952(10)00466-1
DOI: doi:10.1016/j.bcp.2010.06.032
Reference: BCP 10613

To appear in: *BCP*

Received date: 21-4-2010
Revised date: 19-6-2010
Accepted date: 21-6-2010

Please cite this article as: Oppedisano F, Galluccio M, Indiveri C, Inactivation by Hg²⁺ and methylmercury of the glutamine/amino acid transporter (ASCT2) reconstituted in liposomes. Prediction of the involvement of a CXXC motif by homology modelling., *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2010.06.032

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1
2 **Inactivation by Hg²⁺ and methylmercury of the glutamine/amino acid transporter (ASCT2)**
3 **reconstituted in liposomes. Prediction of the involvement of a CXXC motif by homology**
4 **modelling.**
5
6
7
8

9 Francesca Oppedisano, Michele Galluccio and Cesare Indiveri

10
11 Department of Cell Biology, University of Calabria, Via P.Bucci 4c 87036 Arcavacata di Rende,
12 Italy
13

14
15 Correspondence to:

16 Cesare Indiveri,

17 Dipartimento di Biologia Cellulare

18 Università della Calabria

19 Via P.Bucci cubo 4c

20 87036 Arcavacata di Rende (CS)

21 Italy.

22 Tel.: +39-0984-492939

23 Fax: +39-0984-492911

24 e-mail: indiveri@unical.it
25
26
27

28 Running title: effect of methylmercury on glutamine transporter
29
30

31 Key words: methylmercury; glutamine; transport; ASCT2; membrane; liposomes.
32
33

34 Abbreviations: C₁₂E₈, octaethylene glycol monododecyl ether; DTE, 1,4-dithioerythritol.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

The effect of HgCl₂, methylmercury and mersalyl on the glutamine/amino acid (ASCT2) transporter reconstituted in liposomes has been studied. Mercuric compounds externally added to the proteoliposomes, inhibited the glutamine / glutamine antiport catalyzed by the reconstituted transporter. Similar effects were observed by pre-treating the proteoliposomes with the mercurials and then removing unreacted compounds before the transport assay. The inhibition was reversed by DTE, cysteine and N-acetyl-cysteine but not by S-carboxymethyl-cysteine. The data demonstrated that the inhibition was due to covalent reaction of mercuric compounds with Cys residue(s) of the transporter. The IC₅₀ of the transporter for HgCl₂, methylmercury and mersalyl, were 1.4 ± 0.10 μ M, 2.4 ± 0.16 μ M or 3.1 ± 0.19 μ M, respectively. Kinetic studies of the inhibition showed that the reagents behaved as non competitive inhibitor. The presence of glutamine or Na⁺ during the incubation of the mercuric compounds with the proteoliposomes did not exerted any protective effect on the inhibition. None of the compounds was transported by the reconstituted transporter. A metal binding motif CXXC has been predicted as possible site of interaction of the mercuric compounds with the transporter on the basis of the homology structural model of ASCT2 obtained using the glutamate transporter homologue from *P. horikoshii* as template.

1. Introduction

Mercury causes toxic effects in several tissues and organs. In the environment, Hg²⁺ is the most common cationic form and methylmercury is the most common organic mercury compound. It is well known that both cationic and organic mercuric compounds react with thiol groups with very high affinity constants. However, several aspects of the molecular mechanisms of mercury toxicity remain to be elucidated [1-6]. Membrane proteins containing Cys residues exposed to the extracellular environment represent important sites of interaction with mercuric compounds. Transport systems, among membrane proteins, are particularly interesting since they both could

1
2 allow the toxic compounds to enter the cells and could be chemically modified by these compounds
3 with consequent alterations of their function. Indeed, it was reported that some transport systems
4 catalyze the transport of mercuric compounds through biological membranes [2, 7-9]. Furthermore,
5 interaction of mercuric compounds with transport systems of plasma membrane [1, 10-15] and also
6 of mitochondrial membrane [16-17] have been reported to cause alterations of function. In several
7 cases the effects and the sites of interaction of mercurials have been characterized [14-23; 24 and
8 refs. herein]. The study of interaction of mercuric reagents with transport systems for glutamine is
9 still at an initial stage, in spite of the essential role of these transporters in cell homeostasis [25]. It
10 was reported that methylmercury modify the permeability to glutamine of cultured astrocytes by an
11 indirect mechanism based on inhibition of expression of the amino acid transporters ASCT2 and
12 SNAT3; however, this mechanism only partially explained the permeability alteration [26]. The rat
13 glutamine/amino acid transporter ASCT2 which is expressed in kidney, intestine and nervous
14 system besides other tissues [25], was reconstituted in liposomes [27-28]. The transporter was
15 inserted unidirectionally in the proteoliposomal membrane, right-side-out with respect to the cell
16 membrane; thus, the properties of the internal side of the reconstituted transporter correspond to
17 those of the intracellular side and vice versa. The studies in the proteoliposome system, which gives
18 the advantage of reducing the interferences and improving the kinetic resolution in respect to intact
19 cell systems, revealed novel functional properties of this transporter. It was found that the
20 reconstituted transporter is functionally and kinetically asymmetrical, is regulated by intraliposomal
21 (intracellular) ATP and functions by a simultaneous mechanism of transport. In preliminary
22 experiments it was also found that externally added mersalyl, p-hydroxymercurybenzoate and
23 HgCl₂ inhibited the transporter [27-28]. Thus, the proteoliposome experimental model is suitable
24 for investigating the effects of mercurial compounds on the ASCT2 transporter. The effects of
25 HgCl₂ and methylmercury, together with the prototypical protein reagent mersalyl, on the
26 transporter have been characterized in this work. Some thiolic antioxidant compounds can reverse
27 the effect of the mercuric reagents. The relationships among the inhibition and the predicted

structure of the ASCT2 transporter are described.

2. Materials and methods

2.1 Materials. Amberlite XAD-4 and egg yolk phospholipids (3-sn-phosphatidylcholine from egg yolk) were purchased from Fluka; C₁₂E₈ from Anatrace (USA 434 W, Dussel Drive Maumee, OH 43537); L-[³H]glutamine from GE Healthcare (Milano, Italy); Sephadex G-75, L- glutamine, Adenosine 5'-triphosphate, N-acetyl-L-cysteine, L-cysteine, S-carboxymethyl-L-cysteine, methylmercury, HgCl₂, mersalyl and all the other reagents were from Sigma-Aldrich (Milano, Italy).

2.2 Solubilization of the glutamine/amino acid transporter. Brush-border membranes were prepared from rat kidney [29] and stored as previously described [14]. The glutamine/amino acid transporter was solubilized by treating the membrane preparation (50 µl, about 0.15 mg protein) with 1.3 % C₁₂E₈ in a final volume of 150 µl and centrifuged at 13000 g for 4 min at 4° C. The supernatant (extract) was used for the reconstitution.

2.3 Reconstitution of the glutamine/amino acid transporter into liposomes. The glutamine/amino acid transporter was reconstituted by removing the detergent with a hydrophobic chromatography column [16, 30]. In this procedure, the mixed micelles containing detergent, protein and phospholipids were repeatedly passed through the same Amberlite XAD-4 column. The composition of the initial mixture used for reconstitution was: 25 µl of the solubilized protein (25-35 µg protein in 1.3% C₁₂E₈), 75 µl of 10 % C₁₂E₈, 100 µl of 10% egg yolk phospholipids in the form of sonicated liposomes prepared as previously described [30], 30 mM L-glutamine (except where differently specified), 4 mM ATP, 20 mM Hepes/Tris pH 7.0 in a final volume of 700 µl. All the operations were performed at 4 °C. After vortexing, this mixture was passed 16 times at room temperature through the same Amberlite column (0.5 cm diameter x 2.5 cm height) preequilibrated

1
2 with a buffer of the same composition of the initial mixture with the exception of protein, detergent
3 and phospholipid.
4
5
6

7 *2.4 Transport measurements.* To remove the external substrate, 550 μ l of proteoliposomes were
8
9 passed through a Sephadex G-75 column (0.7 cm diameter x 15 cm height) preequilibrated with 20
10 mM HEPES/Tris pH 7.0 and sucrose at an appropriate concentration to balance the internal
11 osmolarity ("unlabeled" proteoliposomes). For efflux measurements, the "unlabeled"
12
13 proteoliposomes (600 μ l), containing 30 mM glutamine, were "prelabeled" by transporter-mediated
14
15 exchange equilibration [16] by incubation with 10 μ l of 0.6 mM [3 H]glutamine at high specific
16
17 radioactivity (2 μ Ci/nmol) for 60 min at 25°C; then, the external radioactivity was removed by
18
19 passing again the proteoliposomes through Sephadex G-75 as described above. Transport was
20
21 started, in the case of uptake, by adding [3 H]glutamine at the indicated concentrations and 50 mM
22
23 Na-gluconate to the "unlabeled" proteoliposomes, or, in the case of efflux, by adding non
24
25 radioactive substrates to the "prelabeled" proteoliposomes. In both cases, transport was stopped by
26
27 adding 20 μ M mersalyl at the desired time interval. In control samples the inhibitor was added at
28
29 time zero according to the inhibitor stop method [31]. The assay temperature was 25 °C. Finally,
30
31 each sample of proteoliposomes (100 μ l) was passed through a Sephadex G-75 column (0.6 cm
32
33 diameter x 8 cm height) to separate the external from the internal radioactivity. Liposomes were
34
35 eluted with 1 ml 50 mM NaCl and collected in 4 ml of scintillation mixture, vortexed and counted.
36
37 For the determination of the specific activity of [3 H]glutamine uptake, the experimental values were
38
39 corrected by subtracting the respective controls (samples inhibited at time zero); the initial rate of
40
41 transport was measured by stopping the reaction after 10 min, i.e., within the initial linear range of
42
43 [3 H]glutamine uptake into the proteoliposomes. [3 H]glutamine efflux activity cannot be calculated
44
45 as specific activity for methodological reasons [16]. It was expressed as % residual intraliposomal
46
47 radioactivity with respect to the radioactivity present in the proteoliposomes at time zero.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 2.5 *Other methods.* The protein concentration was determined by the modified Lowry procedure
3
4 [32].
5

6
7 Mercuric conjugates of cysteine or N-acetylcysteine were formed by incubating HgCl₂,
8
9 methylmercury or mersalyl with cysteine or N-acetylcysteine with 1:1.2 ratio as described in ref.
10
11 [7]. The homology structural model of the ASCT2 was built using the glutamate transporter
12
13 homologue from *P. horikoshii* crystal structure (1XFH) as the template. The amino acid sequence of
14
15 the rat ASCT2 (NP_786934) and the glutamate transporter (NP_143181) were aligned using
16
17 ClustalW and the alignment was manually adjusted as described in ref. [33] for ASCT1, a member
18
19 as ASCT2, of the family of glutamate and neutral amino acid transporters. The optimized alignment
20
21 was used to run the program Modeller 9v7 [34].
22
23
24
25
26
27

28 **3. Results**

29
30 3.1 *Inhibition of the transporter by mercuric reagents.* The effect of HgCl₂, methylmercury and
31
32 mersalyl on the glutamine/amino acid (ASCT2) transporter reconstituted in liposomes was
33
34 investigated. The transport activity was measured as 0.1 mM [³H]glutamine uptake into
35
36 proteoliposomes containing 30 mM glutamine, (glutamine / glutamine homologous antiport) in the
37
38 absence or presence of externally added mercuric reagents. The time courses of the glutamine
39
40 transport are shown in Fig. 1. As previously described [27], the accumulation of labeled glutamine
41
42 into the proteoliposomes depended on the time. It reached the equilibrium at 60 min with a transport
43
44 activity of 140-170 nmol/mg protein in the different experiments (○). The addition during the
45
46 transport assay of each of the reagents strongly inhibited the transport (Δ). In the presence of HgCl₂
47
48 (Fig. 1 A), methylmercury (Fig. 1B) or mersalyl (Fig. 1 C) 75 %, 69 % or 43 % inhibition at 15 min
49
50 was found; at 90 min the transport was still inhibited by 67 %, 47 % or 34 %. The experimental data
51
52 was interpolated in a first order rate equation. The initial transport rate, calculated as the product of
53
54 k and transport at equilibrium, was $11.8 \pm 1.4 \text{ nmol min}^{-1} \text{ mg protein}^{-1}$ in absence of reagents and
55
56
57
58
59
60
61
62
63
64
65

1.7 ± 0.7 , 2.3 ± 0.2 or 5.5 ± 0.2 in the presence of HgCl₂, methylmercury or mersalyl, respectively.

No inhibition was observed in the presence of other chloride salts (NaCl or KCl) instead of HgCl₂, demonstrating the inhibitory effect was due to Hg²⁺. It is known that mercuric compounds react with Cys residues of proteins by Hg-S covalent bond [35]. To verify if the mercuric reagents reacted with Cys residues of the glutamine/amino acid transporter, the effect of DTE, which reverses the Hg-S linkage, was tested. The addition of DTE (▲) after 30 min, to the proteoliposomes treated with mercurials, led to recovery of the transport function, which was almost complete after 60 min from the addition (90 min of transport) for each of the reagents (Fig. 1, A-C). DTE had virtually no effect when added to the control proteoliposomes (●), in the absence of the reagents. To confirm that the inhibition of transport were caused by covalent reaction of the mercuric reagents with the protein, the residual activity of the transporter was determined after pre-incubation of the proteoliposomes with the mercuric reagents and subsequent removal of the unbound compounds. To achieve this objective a strategy previously described for other transporters [36-37] was adopted. After pre-incubation with each of the reagents, the proteoliposomes were passed through size exclusion Sephadex G-75 columns and, then, the transport activity was measured. Proteoliposomes pre-incubated with the reagents (□) showed inhibition of transport of 84 %, 76 % or 47 % at 15 min and 78 %, 72 % or 48 % at 90 min, for HgCl₂ (Fig. 1 A), methylmercury (Fig. 1 B) or mersalyl (Fig. 1 C), respectively. Differently, no inhibition was found, in proteoliposomes treated with DTE (■) after the pre-incubation with the reagents and before the passage through Sephadex G-75 (Fig. 1, A-C) indicating that all the mercurial-protein linkages had been reversed by DTE. The experiments described clearly showed that the inhibition was caused by covalent interaction of the mercuric reagents with one (or more) SH group of the protein. The effect of cysteine, N-acetylcysteine and S-carboxymethylcysteine on the inhibition was also tested. More than 80 % of the transport activity was recovered after incubation of the mercurial treated proteoliposomes with cysteine and N-acetylcysteine except that in the case of HgCl₂ treated proteoliposomes: in this case the recovery of the transport by cysteine

1 was little lower. S-carboxymethylcysteine, which has no free thiol groups, had nearly no effect on
2 the inhibition caused by the mercuric reagents (Fig. 2), confirming the involvement of SH groups of
3 the protein in the reaction. The dependence of the reversal of the inhibition on the concentration of
4 DTE, cysteine and N-acetylcysteine was studied. Maximal effects were observed at concentrations
5 of the thiol containing reagents above 1 mM (not shown).
6
7
8
9
10

11
12
13
14 *3.2 Kinetics of the inhibition of the transporter by mercuric reagents.* The rate of the glutamine /
15 glutamine antiport was determined in the presence of increasing concentration of the reagents. The
16 dose response curves obtained are shown in Fig. 3A. The reagents led to virtually complete
17 inhibition at concentrations above of 3.5 μM , 5 μM or 40 μM in the case of HgCl_2 , methylmercury
18 or mersalyl, respectively; the IC_{50} values, derived from the dose-response curves, were 1.4 ± 0.10
19 μM , $2.4 \pm 0.16 \mu\text{M}$ or $3.1 \pm 0.19 \mu\text{M}$, respectively. A similar experiment was performed measuring
20 the antiport rate after pre-incubation of proteoliposomes with the reagents and subsequent removal
21 of the unbound reagents, as described in the second part of the experiment of Fig. 1. The dose
22 response curves obtained under this condition are reported in Fig. 3B. Results similar to those of
23 Fig. 3A were obtained. The calculated IC_{50} were $2.1 \pm 0.40 \mu\text{M}$, $3.0 \pm 0.12 \mu\text{M}$ or $12 \pm 1.7 \mu\text{M}$ for
24 HgCl_2 , methylmercury or mersalyl, respectively. While in the case of HgCl_2 and methylmercury the
25 IC_{50} values obtained were similar to those calculated for the same reagents added during the
26 transport assay, in the case of mersalyl the IC_{50} value was higher. To get information on the
27 mechanism of inhibition, the dependence of the antiport rate on the extraliposomal glutamine (Figs.
28 4 A-C) or Na^+ (Fig. 5 A-C) concentration in the absence or presence of the reagents was studied.
29 The data, analysed in double reciprocal (Lineweaver-Burk) plots was interpolated by straight lines
30 corresponding to the controls (without reagents) or to different reagent concentrations, with
31 common intersections close to the abscissa. These patterns demonstrate non-competitive inhibition.
32 The half saturation constants of the transporter for the inhibitors (K_i) were derived from the plots.
33 The values of the K_i calculated from Fig. 4 were $0.85 \pm 0.45 \mu\text{M}$, $1.1 \pm 0.15 \mu\text{M}$ or $3.3 \pm 0.50 \mu\text{M}$
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 for HgCl₂, methylmercury and mersalyl, respectively. The values of the K_i calculated from Fig. 5
3 were 1.6 ± 0.10 μM, 1.7 ± 0.19 μM or 1.9 ± 0.10 μM for HgCl₂, methylmercury and mersalyl,
4 respectively. These values are similar to the IC₅₀, as in the case of non-competitive inhibition.
5
6 However, in the case of covalent inhibition a non competitive pattern can be observed also if the
7 inhibitors interact with the substrate binding site [38]. This can be discriminated by protection
8 experiments. If the active and inhibitory sites overlap, the addition of the substrate before the
9 inhibitor causes a reduction of the inhibition. To clarify this point the proteoliposomes were
10 incubated with the glutamine or Na⁺ at different concentrations before the addition of
11 methylmercury. The concentration of the reagent was kept relatively low (close to the IC₅₀) to
12 emphasize the possible protection effect. The residual activity of the transporter in the presence of
13 methylmercury, that was 38 % (62 % inhibition) of the control, was virtually not influenced by the
14 pre-incubation with the substrates, independently on the concentrations (Fig. 6). Very similar results
15 were found in the case of HgCl₂ and mersalyl (not shown). This data confirmed that the reagents
16 bound to a site(s) of the protein which was different from the substrate binding site.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 *3.3 Transport of mercuric compounds.* It was reported that the amino acid transport systems LAT1,
37 LAT2 and B⁰⁺, as well as organic anion transporters are able to transport thiol conjugates of
38 methylmercury, especially as cysteine-S-conjugates [2, 5, 7-9]. To test whether ASCT2 could
39 transport the mercuric reagents as conjugates with cysteine or N-acetylcysteine, the efflux
40 procedure was used. In these experiments the proteoliposomes were pre-labeled by transporter-
41 mediated exchange equilibration (see Materials and methods). After this procedure the
42 proteoliposomes contained internal 30 mM [³H]glutamine. The addition of unlabeled 1.0 mM
43 glutamine or cysteine caused efflux of the internal radioactivity due to the
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

[³H]glutamine_{in}/glutamine_{out} homologous or [³H]glutamine_{in}/cysteine_{out} heterologous antiport; on
the contrary nearly no variations of internal radioactivity were observed after the addition of 1.0
mM N-acetylcysteine, methylmercury, methylmercury-cysteine or methylmercury-N-acetylcysteine

1 conjugates. Similar results were observed after the addition of the unconjugated and conjugated
2 Hg^{2+} and mersalyl (not shown). The small decrease of intraliposomal radioactivity was comparable
3
4 to that found in the absence of external substrate (Fig. 7 A). This data indicated that cysteine was
5
6 transported by the reconstituted ASCT2, as previously shown [27], whereas N-acetylcysteine and
7
8 all the conjugates did not. In another experiment the uptake of [^3H]glutamine into proteoliposomes
9
10 containing the same compounds externally added in the previous experiment was studied. To
11
12 compare the data concerning the methylmercury conjugated with that of the control, the
13
14 concentration of intraliposomal glutamine was kept at the same concentration (1.0 mM) of the
15
16 compounds. Thus, the uptake of [^3H]glutamine in the control proteoliposomes was lower than that
17
18 measured in the experiments of Fig. 1 in which the intraliposomal glutamine concentration was 30
19
20 mM. The accumulation of labeled glutamine in the proteoliposomes in the presence of each of the
21
22 compounds was much lower than the control and comparable or only slightly higher (in the case of
23
24 cysteine) in respect to that found in the absence of intraliposomal substrate, indicating that none of
25
26 the compounds was transported from inside to outside (Fig. 7 B). Similar data were found in the
27
28 presence of intraliposomal unconjugated and conjugated Hg^{2+} and mersalyl (not shown). The data
29
30 also correlates with the previous finding [27] that cysteine is transported from outside to inside (Fig.
31
32 7 A) but not vice versa (Fig. 7 B).
33
34
35
36
37
38
39
40
41
42
43

44 *3.4 Prediction of the inhibition site of the ASCT2 transporter.* It was previously reported that,
45
46 probably, cysteine SH group(s) of the reconstituted ASCT2 transporter are accessible from the
47
48 external side of the proteoliposomes, which corresponds to the extracytoplasmic face of the
49
50 transporter [27]. These functional groups could be involved in the mechanism of inhibition by
51
52 mercurials. To predict which of the Cys residues of the ASCT2 transporter could be involved in
53
54 mercurial binding, a bioinformatic approach was used. As it was previously reported, ASCT2
55
56 belongs to the transporter family SLC1. This family includes also ASCT1 and EAAT1 [39], which
57
58 are homologue of the glutamate transporter Glt_{Ph} , whose structure was resolved by X-ray
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

crystallography [33]. In particular it was reported that ASCT1 has the same consensus sequence of Glt_{Ph} and, hence, it may have the same structural fold. As the human ASCT2 and ASCT1 [40], the rat ASCT2 sequence shares 56 % identity with the rat ASCT1 and the same consensus sequences of Glt_{Ph} (not shown) confirming that ASCT2 belongs to the same transporter family. Thus the ASCT2 sequence has been aligned with the Glt_{Ph} and the alignment has been used to construct the homology model (Fig. 8). The structural model of ASCT2 showed properties similar to those of Glt_{Ph} structure [33, 41]. The protein appears as a wedge with the wide end in contact with the membrane (Fig. 8 A). The tips of three subunits probably come together, as in Glt_{Ph}, forming a trimeric structure. This structure forms, in the middle, a basin exposed towards the extracellular environment (Fig. 8 B). Interestingly, ASCT2 contains a CXXC motif which is typical of metal binding sites in proteins [42]. The two cys residues (Cys-207 and Cys-210) of the motif, highlighted in dark grey (Fig. 8 A and B), are located at the end of a large hydrophilic loop (highlighted in white) which is exposed in the basin towards the external side of the protein. The two Cys are surrounded by four hydrophobic residues, Leu-106, Val-110, Met-225 and Met-227 (not shown).

4. Discussion

In the present study, the proteoliposome system has been used to study the interaction of methylmercury and other mercuric reagents with the reconstituted glutamine/amino acid transporter, which was previously identified with ASCT2 [27-28]. HgCl₂ and methylmercury are the most common forms of mercury to which humans are exposed [4, 6-7]; mersalyl has been used as a prototypal hydrophilic mercury compound which is frequently used as a specific reagent for Cys residues of proteins [35]. Preliminary studies performed with hydrophilic SH reagents, suggested that the reconstituted transporter contains thiol groups of cysteine exposed towards the extraliposomal compartment, which corresponds to the extracellular environment; these data correlated well with the predicted hydropathy profile of ASCT2 [27, 40]. In this profile 2 Cys residues are located in a large hydrophilic loop exposed towards the extracellular environment (not

1 shown and see ref. [27]). Thus, it was expected that the mercuric reagents could interact with one or
2 more of the exposed Cys residue(s) of the transporter. Indeed, the experimental data described in
3
4 this work showed that HgCl₂, methylmercury and mersalyl interact with the transporter leading to
5
6 complete inactivation of its transport function. By experiments based on the pre-incubation of the
7
8 proteoliposomes with the reagents and subsequent removal of the unreacted compounds it was
9
10 demonstrated that the effect was due to covalent binding of the mercuric reagents with one or more
11
12 Cys residue. The kinetic analysis of the inhibition showed a non competitive behavior of the
13
14 reagents which indicated that the site of action should be different from the substrate binding site.
15
16 This hypothesis was confirmed by the finding that the IC₅₀ and the Ki values of the transporter for
17
18 each of the compounds were similar and no protection of the inhibition was observed neither by
19
20 glutamine nor by Na⁺. To better evaluate the relationships between the inhibition by mercuric
21
22 reagents and the structure of the transporter, the homology structural model of the rat ASCT2 was
23
24 built using bioinformatics. In this model the positions of at least two Cys residues correlate well
25
26 with the experimental data. The residues Cys-207 and Cys-210, which belong to a CXXC metal
27
28 binding motif, are located at the end of a large hydrophilic loop of the transporter. The transport
29
30 protein may have a trimeric form as described for the Glt_{ph} [42], with a concave aqueous basin in
31
32 the middle facing towards the extracellular side (Fig. 8 B). The two Cys residues are located
33
34 approximately in the middle of the basin in the proximity of four hydrophobic residues. This may
35
36 explain the finding that the transporter shows higher affinity for methylmercury in respect to the
37
38 more hydrophilic mersalyl which, in addition, exerts stronger inhibition at longer times of
39
40 incubation (see Results section and Fig. 3). The involvement of the CXXC motif in the inhibition is
41
42 in agreement with the higher affinity of the transporter for HgCl₂ (Hg²⁺), which can react with two
43
44 vicinal SH, than to methylmercury and mersalyl, which can react with only one Cys [35]. Among
45
46 other metal cations which are known to react with vicinal SH groups [35], Cu²⁺ strongly inhibited
47
48 the reconstituted transporter (IC₅₀, 20 μM) with a non competitive mechanism; whereas Cd²⁺ and
49
50 Zn²⁺ were poor inhibitors with IC₅₀ > 500 μM (Oppedisano F. and Indiveri C. unpublished
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 results), indicating that the interaction is specific. A third residue, Cys-223, is present in the
2 proximity of the CXXC motif. It cannot be excluded that this Cys residues may also be involved in
3
4 the reaction with mercuric reagents. The inhibition of the transport function upon reaction of the
5
6 mercuric reagents with the Cys residue(s) may be caused by impairment of mobility of the
7
8 hydrophilic loop and/or other domains of the transporter, which is necessary for the transport cycle.
9
10 The implication of the mechanisms of inhibition of the ASCT2 transporter in toxicology may be
11
12 relevant since this transport system plays important functions in several districts among which the
13
14 intestine, kidney and nervous tissue [39-40]. The inhibitory effects have been observed at
15
16 concentrations far below the LD₅₀ of mercuric reagents [1]. Thus, the inactivation of the ASCT2
17
18 transporter may impair the permeability and the metabolism of tissues and organs in which it is
19
20 expressed, under conditions in which the mercuric compound is still below the level of acute
21
22 toxicity. Methylmercury is readily absorbed by the intestine and reaches normally in blood the
23
24 concentration of 1-8 µg/L. Above 200 µg/L (about 1 µM), methylmercury exerts toxic effects [6].
25
26 The IC₅₀ of the transporter for this reagent is in the same range of the toxicity threshold. At the renal
27
28 or intestine level the inactivation of ASCT2 may have little influence on overall amino acid
29
30 adsorption or excretion, due to the antiport mode of functioning. However, it may cause imbalance
31
32 in the composition of the amino acid pool in the cells with, for example, decrease of cysteine, valine
33
34 and methionine which are transported by ASCT2 only from the external to the internal environment
35
36 but not vice versa (see Fig 7 and ref. [27]). The inactivation of ASCT2 will have important
37
38 consequences in the nervous tissue. It was previously reported that methylmercury inhibits the
39
40 expression of the amino acid transporters SNAT1 and ASCT2 in astrocytes. However, this
41
42 mechanism could not explain the effects caused at prolonged times of exposure to methylmercury
43
44 [26]. These effects are explained by the direct inhibition of the transporter, the activity of which is
45
46 suppressed by 10 µM methylmercury (see Fig. 3), i.e., the concentration used in the previous study
47
48 [26]. The effects of cysteine and N-acetylcysteine in reversing the inhibition by mercurials
49
50 correlates well with the use of these antioxidant compounds in mercury detoxification [4].
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 Differently from other amino acid or anion transporters [2, 5, 7-9] ASCT2 is not involved in the
3 absorption of mercurials nor as free molecules neither as conjugates.
4
5
6

7 **Acknowledgements**

8
9 This work was supported by grants from Ministero dell'Università e della Ricerca (PRIN 2006
10 grant no. 2006054479) and from University of Calabria (ex 60 % 2008-2009).
11
12
13
14
15
16

17 **5. References**

- 18
19 [1] Zalups RK. Molecular interactions with mercury in the kidney. *Pharmacol Rev* 2000;
20 52: 113-43.
21
22 [2] Bridges CC, Zalups RK. Molecular and ionic mimicry and the transport of toxic metals.
23 *Toxicol Appl Pharmacol* 2005; 204: 274-308.
24
25 [3] Newland MC, Paletz EM, Reed MN. Lactational exposure to mercury in experimental
26 models. *NeuroToxicology* 2009; 30: 160-3.
27
28 [4] Rooney JP. The role of thiols, dithiols, nutritional factors and interacting ligands in the
29 toxicology of mercury. *Toxicology* 2007; 234: 145-56.
30
31 [5] Hirooka T, Fujiwara Y, Minami Y, Ishii A, Ishigooka M, Shinkai Y et al. Cell-density-
32 dependent methylmercury susceptibility of cultured human brain microvascular
33 pericytes. *Toxicology in Vitro* 2010; 24: 835-41.
34
35 [6] ATSDR: Agency for Toxic Substance and Disease Registry. Toxicological Profile for
36 Mercury. U.S. Department of Health and Humans Services, Public Health Services,
37 Centers for Disease Control, Atlanta, GA. 2003.
38
39 [7] Bridges CC, Zalups RK. System b^{0,+} and the transport of thiol-s-conjugates of
40 methylmercury. *J Pharmacol Exp Ther* 2006; 319: 948-56.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [8] Yin Z, Jiang H, Syversen T, Rocha JB, Farina M, Aschner M. The methylmercury-L-cysteine conjugate is a substrate for the L-type large neutral amino acid transporter. *J Neurochem* 2008; 107: 1083-90.
- [9] Heggland I, Kaur P, Syversen T. Uptake and efflux of methylmercury in vitro: comparison of transport mechanisms in C6, B35 and RBE4 cells. *Toxicol In Vitro* 2009; 23: 1020-7.
- [10] Ritzhaupt A, Wood IS, Ellis A, Hosie KB, Shirazi-Beechey SP. Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate. *J Physiol* 1998; 513: 719-32.
- [11] Schweri MM. Mercuric chloride and p-chloromercuriphenylsulfonate exert a biphasic effect on the binding of the stimulant [3H]methylphenidate to the dopamine transporter. *Synapse* 1994; 16: 188-94.
- [12] Zhang ZH, Solomon AK. Effect of pCMBS on anion transport in human red cell membranes. *Biochim Biophys Acta* 1992; 1106: 31-9.
- [13] Zeidel ML, Albalak A, Grossman E, Carruthers A. Role of glucose carrier in human erythrocyte water permeability. *Biochemistry* 1992; 31: 589-96.
- [14] Pochini L, Oppedisano F, Indiveri C. Reconstitution into liposomes and functional characterization of the carnitine transporter from renal cell plasma membrane. *Biochim Biophys Acta* 2004; 1661: 78-86.
- [15] Oppedisano F, Indiveri C. Reconstitution into liposomes of the B⁰-like glutamine-neutral amino acid transporter from renal cell plasma membrane. *Biochim Biophys Acta* 2008; 1778: 2258-65.
- [16] Palmieri F, Indiveri C, Bisaccia F, Iacobazzi V. Mitochondrial metabolite carrier proteins: purification, reconstitution, and transport studies. *Methods Enzymol* 1995; 260: 349-369.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [17] Palmieri F, Indiveri C, Bisaccia F, Kramer R. Functional properties of purified and reconstituted mitochondrial metabolite carriers. *J Bioenerg Biomembr* 1993; 25: 525-35.
- [18] Verkman AS. Water channels in cell membranes. *Annu Rev Physiol* 1992; 54: 97-108.
- [19] Anner BM, Moosmayer M. Mercury inhibits Na-K-ATPase primarily at the cytoplasmic side. *Am J Physiol* 1992; 262: F843-8.
- [20] Anner BM, Moosmayer M, Imesch E. Mercury blocks Na-K-ATPase by a ligand-dependent and reversible mechanism. *Am J Physiol* 1992; 262: F830-6.
- [21] Murata K, Mitsuoka K, Hirai T, Walz T, Agre P, Heymann JB et al. Structural determinants of water permeation through aquaporin-1. *Nature* 2000; 407: 599-605.
- [22] Capobianco L, Bisaccia F, Mazzeo M, Palmieri F. The mitochondrial oxoglutarate carrier: sulfhydryl reagents bind to cysteine-184, and this interaction is enhanced by substrate binding. *Biochemistry* 1996; 35: 8974-80.
- [23] Wellner M, Monden I, Keller K. The role of cysteine residues in glucose-transporter-GLUT1-mediated transport and transport inhibition. *Biochem J* 1994; 299: 813-7.
- [24] Tonazzi A, Indiveri C. Chemical modification of the mitochondrial ornithine/citrulline carrier by SH reagents: effects on the transport activity and transition from carrier to pore-like function. *Biochim Biophys Acta* 2003; 1611: 123-30.
- [25] Broer S. Amino acid transport across mammalian intestinal and renal epithelia. *Physiol Rev* 2008; 88: 249-86.
- [26] Yin Z, Milatovic D, Aschner JL, Syversen T, Rocha JB, Souza DO et al. Methylmercury induces oxidative injury, alterations in permeability and glutamine transport in cultured astrocytes. *Brain Res* 2007; 1131: 1-10.
- [27] Oppedisano F, Pochini L, Galluccio M, Cavarelli M, Indiveri C. Reconstitution into liposomes of the glutamine/amino acid transporter from renal cell plasma membrane:

functional characterization, kinetics and activation by nucleotides. *Biochim Biophys Acta* 2004; 1667: 122-31.

- [28] Oppedisano F, Pochini L, Galluccio M, Indiveri C. The glutamine/amino acid transporter (ASCT2) reconstituted in liposomes: transport mechanism, regulation by ATP and characterization of the glutamine/glutamate antiport. *Biochim Biophys Acta* 2007; 1768: 291-8.
- [29] Biber J, Stieger B, Haase W, Murer H. A high yield preparation for rat kidney brush border membranes. Different behaviour of lysosomal markers. *Biochim Biophys Acta* 1981; 647: 169–176.
- [30] Kramer R, Heberger C. Functional reconstitution of carrier proteins by removal of detergent with a hydrophobic ion exchange column. *Biochim Biophys Acta* 1986; 863: 289–296.
- [31] Palmieri F, Klingenberg M. Direct methods for measuring metabolite transport and distribution in mitochondria. *Methods Enzymol* 1979; 56: 279-301.
- [32] Dulley JR, Grieve PA. A simple technique for eliminating interference by detergents in the Lowry method of protein determination. *Anal Biochem* 1975; 64: 136–141.
- [33] Yernool D, Boudker O, Jin Y, Gouaux E. Structure of a glutamate transporter homologue from *Pyrococcus horikoshii*. *Nature* 2004; 431: 811-8.
- [34] Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol* 1993; 234: 779-815.
- [35] van Iwaarden PR, Driessen AJ, Konings WN. What we can learn from the effects of thiol reagents on transport proteins. *Biochim Biophys Acta* 1992; 1113: 161-70.
- [36] Tonazzi A, Giangregorio N, Palmieri F, Indiveri C. Relationships of Cysteine and Lysine residues with the substrate binding site of the mitochondrial ornithine/citrulline carrier: an inhibition kinetic approach combined with the analysis of the homology structural model. *Biochim Biophys Acta* 2005; 1718: 53-60.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [37] Pochini L, Galluccio M, Scumaci D, Giangregorio N, Tonazzi A, Palmieri F et al. Interaction of beta-lactam antibiotics with the mitochondrial carnitine/acylcarnitine transporter. *Chem Biol Interact* 2008; 173: 187-94.
- [38] Webb JL. Enzyme and metabolic inhibitors. Academic Press, New York and London; 1966.
- [39] Kanai Y, Hediger MA. The glutamate/neutral amino acid transporter family SLC1: molecular physiological and pharmacological aspects. *Pflugers Arch* 2004; 447: 469-79.
- [40] Utsunomiya-Tate N, Endou H, Kanai Y. Cloning and functional characterization of a system ASC-like Na⁺-dependent neutral amino acid transporter. *J Biol Chem* 1996; 271: 14883–90.
- [41] Reyes N, Ginter C, Boudker O. Transport mechanism of a bacterial homologue of glutamate transporters. *Nature* 2009; 462: 880-5.
- [42] Vats N, Lee SF. Characterization of a copper-transport operon, copYAZ, from *Streptococcus mutans*. *Microbiology* 2001;147: 653-62.

Legends to Figures

1
2 Fig. 1. Effect of mercuric reagents on the glutamine antiport mediated by the reconstituted
3
4 transporter. After passage of the reconstituted proteoliposomes through Sephadex G-75 columns,
5
6 transport was measured adding 0.1 mM [³H]glutamine and 50 mM Na-gluconate in the presence of:
7
8 (○), no additions; (●) 2 mM DTE; (Δ), 3 μM of HgCl₂ (A), methylmercury (B) or mersalyl (C);
9
10 (▲), 2 mM DTE, added 30 min after the [³H]glutamine to an aliquot of proteoliposomes. In (□), 6
11
12 μM HgCl₂ (A), methylmercury (B) or mersalyl (C) was added 2 min before and in (■) DTE 1 min
13
14 before the passage of the proteoliposomes through the Sephadex G-75 columns. Transport was
15
16 started as described above. The transport reaction was stopped at the indicated times, adding 20 μM
17
18 mersalyl. The values are means ± S.D. from three experiments.

19
20
21
22
23
24 Fig. 2. Effect of cysteine, N-acetylcysteine and S-carboxymethylcysteine on the inhibition of the
25
26 glutamine antiport by mercuric reagents. 3 μM HgCl₂, 6 μM methylmercury or 6 μM mersalyl and,
27
28 after 1 min, 2 mM cysteine (Cys), N-acetylcysteine (NAC) and S-carboxymethylcysteine (CMC)
29
30 were added to the reconstituted proteoliposomes, where indicated. After passage of the
31
32 proteoliposomes through Sephadex G-75 columns transport was measured adding 0.1 mM
33
34 [³H]glutamine and 50 mM Na-gluconate and stopped after 30 min, adding 20 μM mersalyl.

35
36
37
38
39 Fig. 3. Dose-response curves for the inhibition of the reconstituted transporter by mercuric reagents.
40
41 After passage of the reconstituted proteoliposomes through Sephadex G-75 columns, transport was
42
43 measured adding 0.1 mM [³H]glutamine and 50 mM Na-gluconate (A) in the presence of HgCl₂
44
45 (●), methylmercury (■) or mersalyl (▲) at the indicated concentrations. In (B) HgCl₂ (●),
46
47 methylmercury (■) or mersalyl (▲) at indicated concentrations were added to the proteoliposomes
48
49 before the passage of the proteoliposomes through the Sephadex G-75 columns and, then, the
50
51 transport was started as described above. In all the samples the transport reaction was stopped after
52
53 10 min, adding 20 μM mersalyl. Percent residual activity with respect to the control (92 ± 16
54
55 nmol/mg protein) is reported. The values are means ± S.D. from three experiments.
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Fig. 4. Kinetic analysis of the inhibition of the reconstituted transporter by mercuric reagents at variable glutamine concentrations. Transport was measured adding [^3H]glutamine at the indicated concentrations and 50 mM Na-gluconate at time zero to proteoliposomes containing 30 mM glutamine in the absence (\circ) or in the presence of 1.5 μM (\bullet) or 3.0 μM (\square) HgCl_2 (A), or in the presence of 2.0 μM (\bullet) or 5.0 μM (\square) methylmercury (B) or in the presence of 3.0 μM (\bullet) or 5.0 μM (\square) mersalyl (C). The transport reaction was stopped at 10 min, adding 20 μM mersalyl. The experimental data were plotted according to Lineweaver-Burk as reciprocal transport rate vs reciprocal glutamine concentrations. The values are means \pm S.D. from three experiments.

Fig. 5. Kinetic analysis of the inhibition of the reconstituted transporter by mercuric reagents at variable Na^+ concentrations. Transport was measured adding 0.1 mM [^3H]glutamine and the indicated concentrations of Na-gluconate at time zero to proteoliposomes containing 30 mM glutamine in the absence (\circ) or in the presence of 1.5 μM (\bullet) or 3.0 μM (\square) HgCl_2 (A), or in the presence of 2.0 μM (\bullet) or 5.0 μM (\square) methylmercury (B) or in the presence of 3.0 μM (\bullet) or 5.0 μM (\square) mersalyl (C). The transport reaction was stopped at 10 min, adding 20 μM mersalyl. The experimental data were plotted according to Lineweaver-Burk as reciprocal transport rate vs reciprocal Na-gluconate concentrations. The values are means \pm S.D. from three experiments.

Fig. 6. Influence of substrate on the inhibition of the reconstituted transporter by mercuric reagents. Reconstituted proteoliposomes were treated as described in the figure before the transport assay: where indicated, glutamine or Na-gluconate at the concentrations (mM) in brackets were added to proteoliposome samples 1 min before 3.0 μM methylmercury. All samples were then passed through Sephadex G-75 columns to remove the unreacted inhibitor and substrates; transport was started adding 0.1 mM [^3H]glutamine and stopped after 30 min adding 20 μM mersalyl. Percent residual activity with respect to the control (167 ± 27 nmol/mg protein) is reported. The values are means \pm S.D. from three experiments.

Fig. 7. Time course of [^3H]glutamine efflux and uptake in proteoliposomes mediated by the reconstituted transporter in the presence of mercuric conjugates as counter-substrates. (A) Efflux or

1 (B) uptake of [³H]glutamine in proteoliposomes was measured in the presence of: (A) external 50
2 mM Na-gluconate and 1.0 mM glutamine (●), 1.0 mM cysteine (□), 1.0 mM N-acetylcysteine (■),
3
4 1.0 mM methylmercury (Δ), 1.0 mM methylmercury-cysteine (▲), 1.0 mM methylmercury-N-
5
6 acetylcysteine (∇) or buffer alone (○); (B) external 50 mM Na-gluconate and internal 1.0 mM
7
8 glutamine (●), 1.0 mM cysteine (□), 1.0 mM N-acetylcysteine (■), 1.0 mM methylmercury (Δ), 1.0
9
10 mM methylmercury-cysteine (▲), 1.0 mM methylmercury-N-acetylcysteine (∇) or buffer alone (○).
11
12
13 The transport reaction was stopped at the indicated times, adding 20 μM mersalyl. The values are
14
15 means ± S.D. from three experiments.
16
17
18

19 Fig. 8. Homology structural model of rat ASCT2. (A) Ribbon diagram viewing the transporter
20
21 from the lateral side; the membrane is indicated by a black line with external and internal sides.
22
23 (B) Ribbon diagram viewing the hypothetical trimeric form of the transporter from the top
24
25 (extracellular side); the basin protruding towards the extracellular side is indicated by a dotted
26
27 circle. Cys-207 and Cys-210 are in dark grey. The large loop protruding towards the extracellular
28
29 environment is in white. The homology model has been represented using the molecular program
30
31 SpdbViewer 4.01.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65








Figure2

Preprint















Figure6





Manuscript





...cause inactivation of ASCT2 transporter reversed by Cys and N-Acetyl-Cys not CarboxyMethyl-Cys. The targets may be extracellular facing **CXXC** motifs of the predicted ASCT2 structure.

